Device type · CDZ
Radioimmunoassay, Testosterones And Dihydrotestosterone
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
CDZ
Clinical Chemistry
Device class
Class I
FDA decisions since 2015
17
510(k), De Novo and PMA
Adverse event reports
22
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Radioimmunoassay, Testosterones And Dihydrotestosterone
- Product code
- CDZ
- Device class
- Class I
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1680
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for CDZ
Latest FDA decisions
The 8 newest of 17 since 2015.
Immunodiagnostic Systems Limited
K252728 · Decided Apr 15, 2026 · 230 days after receipt
Device type: Radioimmunoassay, Testosterones And Dihydrotestosterone (CDZ) · Laboratory Medicine & Pathology
Immunodiagnostic Systems Limited
K240865 · Decided Oct 23, 2024 · 209 days after receipt
Device type: Radioimmunoassay, Testosterones And Dihydrotestosterone (CDZ) · Laboratory Medicine & Pathology
- Access SHBG510(k)
K233480 · Decided Feb 8, 2024 · 105 days after receipt
Device type: Radioimmunoassay, Testosterones And Dihydrotestosterone (CDZ) · Laboratory Medicine & Pathology
14 more FDA decisions with a free account
Reports received
22
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
21
95% of reports
Injury reports
1
4.5% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 1 | 0 | 0 | 0 |
| Jan 24 | 0 | 1 | 0 | 0 |
| Feb 24 | 1 | 0 | 0 | 0 |
| Mar 24 | 1 | 0 | 0 | 0 |
| Apr 24 | 0 | 1 | 0 | 0 |
| May 24 | 1 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 1 | 0 | 0 | 0 |
| Aug 24 | 1 | 0 | 0 | 0 |
| Sep 24 | 2 | 2 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 2 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 3 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 1 | 0 | 0 | 0 |
| Aug 25 | 2 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 3 | 0 | 0 | 0 |
| Nov 25 | 1 | 0 | 0 | 0 |
| Dec 25 | 6 | 0 | 0 | 0 |
| Jan 26 | 1 | 0 | 0 | 0 |
| Feb 26 | 1 | 0 | 0 | 0 |
| Mar 26 | 1 | 0 | 0 | 0 |
| Apr 26 | 2 | 0 | 0 | 0 |
| May 26 | 2 | 0 | 0 | 0 |
| Jun 26 | 1 | 1 | 0 | 0 |
| Jul 26 | 2 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 4 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results13
- Non Reproducible Results10
- Low Test Results9
4 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions21
- Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2746-2026 · Started Jun 12, 2026 · Posted by FDA Jul 16, 2026
Reason given: The Test cup lot F level 1 low-quality control results values for the device were lower than expected on the Automated Immunoassay Analyzer (AIA) which could cause falsely elevated or falsely low total testosterone results. Such erroneous test results may lead to additional testing/diagnostic interventions and in...
Cause as FDA categorized it: Component design/selection
- Men s Hormone TestOpen, Classified
Z-0788-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025
Reason given: Distribution without premarket approval/clearance.
Cause as FDA categorized it: No Marketing Application
- Access Testosterone assay, Catalog Number 33560Open, Classified
Z-1901-2025 · Started May 5, 2025 · Posted by FDA Jun 2, 2025
Reason given: Inadequate preventative maintenance (PM) performed on the scales of the RPL5 fill line, led to splashing (cross-contamination) between the wells of testosterone reagent packs lot 538081, which could potentially result in up to a 34% increase or a 23% decrease in patient results.
Cause as FDA categorized it: Equipment maintenance
16 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.